United States Patent 7,736,665: Claim Scope, Patent Expiration, Probuphine Landscape, and Generic Entry Risk

U.S. Patent No. 7,736,665 protects a specific method of treating opioid addiction with a subcutaneous buprenorphine implant. The core claim requires an EVA-based polymer matrix, continuous release through surface pores, a sustained plasma concentration of approximately 0.1 to 1 ng/mL for at least three months, and the absence of both an impermeable coating and external medical equipment. The patent was assigned to Titan Pharmaceuticals and is associated with the Probuphine implant platform.

The patent is narrower than a general buprenorphine implant patent. A competing product must satisfy every limitation of an asserted claim to create literal infringement. The principal commercial significance lies in claims covering the formulation, extrusion process, implant dimensions, buprenorphine loading, and ethanol washing step.

What does U.S. Patent 7,736,665 protect?

The patent protects a treatment method rather than an unrestricted composition or device claim. Claim 1 requires the following elements:

Claim element	Required limitation
Patient	Human with opioid addiction
Route	Subcutaneous implantation
Active ingredient	Buprenorphine
Polymer	Ethylene vinyl acetate copolymer, or EVA
Device structure	Polymeric matrix with buprenorphine blended into EVA
Release mechanism	Continuous in vivo release through pores opening at the matrix surface
Duration	Steady-state plasma level for at least about three months
Coating limitation	No coating impermeable to buprenorphine
Equipment limitation	No external medical equipment
Pharmacokinetic result	Therapeutically effective steady-state plasma buprenorphine level of approximately 0.1 to 1 ng/mL

The claim combines structural, process-independent, therapeutic, and pharmacokinetic limitations. An accused product must therefore be evaluated against both its physical design and its clinical release profile.

The claim does not require the marketed Probuphine configuration of four implants or a six-month treatment period. A device that maintains the claimed plasma range for only three months could fall within claim 1 if the other limitations are met.

How broad is claim 1 of patent 7,736,665?

Claim 1 has meaningful breadth at the device level but substantial narrowing limitations at the infringement level.

Structural scope

The claim covers a matrix in which buprenorphine is blended with EVA. It does not expressly require:

A particular implant count;
A particular implant shape;
A particular buprenorphine loading percentage;
33% vinyl acetate;
A specific extrusion method;
A six-month release period;
A particular diameter or length;
A particular brand name or commercial product.

The absence of an express loading percentage means that claim 1 can reach formulations outside the concentrations recited in dependent claims 3 through 5, provided the device otherwise satisfies claim 1.

Release-performance scope

The claim requires continuous release through pores that open to the matrix surface. This limitation distinguishes the claimed device from systems that release buprenorphine primarily through:

A drug-permeable membrane;
A reservoir with a rate-controlling coating;
An electronic pump;
External infusion equipment;
A biodegradable matrix that releases through polymer erosion rather than the claimed pore pathway.

The claim also requires a pharmacokinetic outcome: a steady-state plasma concentration of about 0.1 to about 1 ng/mL. This limitation can create litigation complexity because infringement may depend on clinical or pharmacokinetic evidence rather than only on inspection of the product.

Treatment-method scope

The claim is limited to treating opioid addiction in a human. Use of the same device for another indication may not literally satisfy the claim. The claim also requires actual subcutaneous implantation, not merely manufacture, sale, or possession of the device.

A product manufacturer could nevertheless face indirect-infringement exposure if it supplies the device with instructions that encourage the claimed implantation method. Prescriber and healthcare-provider conduct would also be relevant to induced-infringement analysis under 35 U.S.C. §271(b).

What do claims 2 through 9 add?

The dependent claims narrow the patent around the commercial formulation and manufacturing process.

Claim	Added limitation	Commercial significance
2	EVA contains about 33% vinyl acetate	Targets a specific EVA grade or composition
3	Device contains about 10% to about 85% buprenorphine	Establishes a broad loading range
4	About 50% buprenorphine	Covers a specific loading embodiment
5	About 75% buprenorphine	Covers a higher-loading embodiment
6	Device is produced by extrusion	Protects a manufacturing route
7	Diameter about 1.5 to 5 mm and length about 0.5 to 7 cm	Covers physical implant dimensions
8	Device is washed with ethanol before implantation	Protects a preimplantation treatment
9	Ethanol washing removes surface buprenorphine and reduces initial burst release	Adds a functional release-control result

Claims 4 and 5 are alternative species within the range of claim 3. They do not require both 50% and 75% buprenorphine. Claim 7 depends on the extrusion limitation in claim 6 and therefore requires both the specified process and dimensions.

Claim 9 is particularly important because it adds a functional result to the ethanol-washing step. Evidence would likely focus on surface drug removal and comparative burst-release testing against an unwashed device.

What formulations are protected by patent 7,736,665?

The strongest formulation position is an extruded EVA implant using approximately 33% vinyl acetate EVA and a buprenorphine loading of approximately 50% or 75%. The claims also reach broader formulations through claim 1 and claim 3.

Formulation coverage

The disclosed claim set covers:

Buprenorphine blended directly into EVA;
EVA with approximately 33% vinyl acetate;
Buprenorphine loading from approximately 10% to 85%;
A 50% buprenorphine formulation;
A 75% buprenorphine formulation;
A noncoated matrix with surface pores;
Ethanol-washed implants designed to reduce initial burst release.

The claims do not expressly require a particular buprenorphine salt, particle size, excipient, sterilization technique, or implant number. Those features may be relevant to infringement or validity only if they affect a claimed limitation.

What the patent does not clearly cover

The patent does not, based on the supplied claims, independently claim:

Sublingual buprenorphine products;
Buccal films or tablets;
Oral formulations;
Transdermal patches;
Injectable depot formulations;
A drug reservoir surrounded by an impermeable or rate-controlling coating;
An implant that uses external equipment;
A device lacking EVA;
A device that does not produce the claimed plasma concentration.

A formulation that uses a different polymer may avoid literal infringement of the supplied claims, although other patents could apply.

When does U.S. Patent 7,736,665 lose exclusivity?

Patent 7,736,665 issued on June 15, 2010. Public patent records identify a December 2003 filing lineage and a term extending into 2024, subject to the patent’s recorded patent-term adjustment and any applicable terminal disclaimer. The patent is therefore no longer a live blocking patent after the end of its recorded term.

Event	Date
Earliest reported priority period	December 2002
U.S. nonprovisional filing lineage	December 2003
Patent issued	June 15, 2010
Expected statutory term endpoint	December 2023 to December 2024, depending on recorded term adjustment
Current practical position	No longer a principal unexpired barrier after term expiration

The operative date is the expiration date shown in the USPTO patent record, not the issue date. Patent 7,736,665 should not be treated as an enforceable barrier after expiration. Regulatory exclusivity, other Orange Book patents, settlement restrictions, and separate patents can still affect market entry.

The patent’s expiration does not automatically authorize a competing product. A follow-on product must also address other unexpired patents, FDA requirements, manufacturing controls, and potential product-specific regulatory exclusivity.

What is the FDA and Orange Book status of the Probuphine product?

Probuphine is a buprenorphine implant approved by the FDA in 2016 for maintenance treatment of opioid dependence in patients who are clinically stable on low-to-moderate doses of transmucosal buprenorphine. The product contains four small implants placed subcutaneously in the upper arm and is designed to deliver buprenorphine for approximately six months.[2]

The product was developed by Titan Pharmaceuticals and commercialized through Braeburn Pharmaceuticals under a collaboration and licensing arrangement. Probuphine is regulated as a prescription drug product, and its NDA history is separate from the patent grant itself.

FDA approval does not establish patent validity or infringement. The Orange Book identifies patents submitted by an NDA holder, but it does not determine whether those patents are valid, enforceable, or infringed.[3]

Regulatory exclusivity versus patent exclusivity

The principal exclusivity categories are distinct:

Exclusivity type	Relevance to Probuphine
New chemical entity exclusivity	Limited relevance because buprenorphine was previously approved
Three-year clinical-investigation exclusivity	Could apply to the approved implant application or new conditions, depending on FDA listing
Pediatric exclusivity	Adds six months only if granted
Patent term	Depends on each listed patent and its recorded expiration
Orphan exclusivity	Not the principal exclusivity basis for opioid-dependence treatment

A competitor must evaluate the FDA Orange Book listing and the current NDA status rather than relying solely on Patent 7,736,665.

Which companies challenged or could challenge the Probuphine patent estate?

The most likely challenger profile is a generic or specialty-pharmaceutical company developing a long-acting buprenorphine implant or another dosage form intended to compete with Probuphine.

A Paragraph IV certification could challenge an Orange Book-listed patent as invalid, unenforceable, or not infringed. The patent owner could then file an infringement action under the Hatch-Waxman framework, potentially triggering a statutory stay of FDA approval for up to 30 months under 21 U.S.C. §355(j)(5)(B)(iii).

The supplied record does not establish a particular Paragraph IV notice, ANDA filer, settlement agreement, or active litigation involving Patent 7,736,665. Patent expiration materially reduces the value of a late Paragraph IV challenge directed only to this patent. A challenge can remain commercially relevant if related patents have later expiration dates.

What patent litigation affects Probuphine and patent 7,736,665?

Patent 7,736,665 is a method patent. Litigation would likely focus on five issues:

Whether the accused implant uses an EVA matrix.
Whether buprenorphine is blended into the matrix rather than held in a separate reservoir.
Whether release occurs through surface pores.
Whether the device produces the claimed steady-state plasma concentration.
Whether the accused use is treatment of opioid addiction in a human.

Validity challenges could target written description, enablement, anticipation, obviousness, indefiniteness, and the scope of the pharmacokinetic limitations. The claimed plasma range may be vulnerable if prior art disclosed substantially similar buprenorphine release profiles or if the specification does not adequately support the full scope of the claimed range.

A noninfringement defense could rely on a different polymer, a coated reservoir system, a different release mechanism, a plasma concentration outside the claimed range, or a use that does not induce the claimed treatment method.

No settlement terms should be inferred from the patent grant or FDA approval. A settlement involving a related patent would not necessarily resolve claims under Patent 7,736,665 unless the agreement expressly covers it.

How strong is the patent estate for Probuphine?

Patent 7,736,665 has a focused but commercially relevant claim structure. Its strength is highest against a product that copies the core design:

EVA matrix;
Direct buprenorphine blending;
Surface-pore release;
Subcutaneous implantation;
At least three months of steady-state exposure;
No impermeable coating.

Its strength is weaker against alternative delivery technologies. The claim does not cover all long-acting buprenorphine products and does not prevent competition from injectable depots, biodegradable implants, polymer systems using different materials, or nonimplant dosage forms.

Strength factors

Factor	Assessment
Claim differentiation	Strong; claims combine formulation, structure, release, and treatment limitations
Design-around risk	Moderate to high; polymer and delivery architecture can be changed
Clinical-proof burden	Meaningful; plasma-level limitations may require pharmacokinetic evidence
Manufacturing coverage	Narrower; extrusion and dimensions appear only in dependent claims
Product coverage	Focused on the EVA implant platform
Remaining term	No longer the principal long-term barrier after expiration
Regulatory relevance	Dependent on FDA listing and NDA-specific exclusivity

How does patent 7,736,665 compare with later Probuphine patents?

Later patents in the Probuphine family or related implant portfolio may claim narrower improvements, manufacturing methods, implant configurations, release performance, or clinical-use parameters. Those patents must be reviewed separately because a later patent can remain enforceable after Patent 7,736,665 expires.

The practical analysis should separate three layers:

Foundational platform claims, including the EVA-buprenorphine matrix.
Product-specific claims covering the approved implant configuration.
Manufacturing, sterilization, implantation, dosing, and treatment-method claims.

Patent 7,736,665 is most important as a foundational platform patent. It is not sufficient by itself to map the complete freedom-to-operate position for a Probuphine competitor.

What generic launch risks exist after patent expiration?

After expiration, the leading risks shift from infringement of Patent 7,736,665 to regulatory and technical barriers.

Generic and follow-on risks

A competing applicant may face:

Difficulty demonstrating equivalence for an implant;
Complex bioequivalence and pharmacokinetic requirements;
Drug-device combination-product review;
Manufacturing validation for implant dimensions and drug loading;
Sterility and extractables/leachables testing;
Controlled-substance handling requirements;
Surgical implantation and removal procedures;
Residual unexpired patents;
FDA exclusivity or approval timing restrictions;
Commercial limitations caused by the small size of the implant market.

Because Probuphine is an implant rather than a conventional tablet or film, an ANDA may not be sufficient for every competing product design. A 505(b)(2) application or a new NDA may be more appropriate where the product differs materially in formulation, device design, implantation procedure, or clinical performance.[2]

What licensing deals affect the commercial landscape?

Titan Pharmaceuticals licensed commercial rights for Probuphine to Braeburn Pharmaceuticals. The arrangement supported development, regulatory approval, and commercialization of the product. The existence of a license does not extend the statutory term of Patent 7,736,665. It can, however, affect royalty obligations, control of litigation, product supply, and access to manufacturing know-how.

Patent rights and know-how should be analyzed separately. An expired patent may no longer block use of the claimed invention, while confidential manufacturing information, quality systems, process controls, and trade secrets may continue to have commercial value.

What geographic coverage does the patent provide?

U.S. Patent 7,736,665 provides rights only in the United States. Foreign protection requires separate national or regional patents. Patent expiration, validity, claim language, patent-term adjustment, and litigation outcomes can differ by jurisdiction.

A global freedom-to-operate review should separately examine:

United States;
European Patent Convention states;
Canada;
Australia;
Japan;
China;
Other jurisdictions where long-acting opioid-treatment products may be commercialized.

A U.S. patent cannot prevent manufacture and sale outside the United States unless separate foreign rights exist or cross-border conduct creates U.S. infringement exposure.

What manufacturing and intellectual-property barriers remain?

The principal technical barrier is reproducing a stable, implantable EVA matrix that delivers buprenorphine at a controlled rate without an impermeable coating. Key process variables include:

EVA vinyl acetate content;
Buprenorphine loading;
Drug particle distribution;
Extrusion temperature and shear;
Implant diameter and length;
Surface porosity;
Residual solvent removal;
Ethanol washing;
Sterilization conditions;
Initial burst control;
Long-term release uniformity.

A competitor may avoid a literal claim by changing the polymer or delivery architecture. That change may create a new regulatory development program and may also lose the release profile that makes the product clinically useful.

Key Takeaways

Patent 7,736,665 covers a method using a subcutaneous buprenorphine implant made from a buprenorphine-EVA polymer matrix.
Claim 1 requires at least three months of steady-state release, surface-pore delivery, a plasma level of approximately 0.1 to 1 ng/mL, and no impermeable coating or external equipment.
Dependent claims target 33% vinyl acetate EVA, 10% to 85% buprenorphine loading, 50% and 75% formulations, extrusion, implant dimensions, and ethanol washing.
The patent is narrower than a general long-acting buprenorphine patent because it requires a specific polymer matrix and release mechanism.
The patent term ended or reached its statutory endpoint in the 2023-2024 period, subject to the USPTO-recorded term adjustment.
Patent expiration does not eliminate risks from later patents, FDA exclusivity, combination-product requirements, or manufacturing know-how.
Probuphine is an FDA-approved four-implant buprenorphine product associated with Titan Pharmaceuticals and Braeburn Pharmaceuticals.
No Paragraph IV challenge, settlement, or active litigation should be attributed to this patent without a separate current court and Orange Book review.
Biosimilar analysis is not applicable because buprenorphine is a small-molecule active ingredient. The relevant pathways are generic, 505(b)(2), or new-NDA strategies.

FAQs About U.S. Patent 7,736,665

Does patent 7,736,665 cover all buprenorphine implants?

No. It covers implants that satisfy the claimed EVA matrix, surface-pore release, subcutaneous treatment, duration, and plasma-concentration limitations. Implants using different polymers or release architectures may fall outside the supplied claims.

Does the patent require four Probuphine implants?

No. The claims provided do not require four implants. They require at least one implantable device. The four-implant commercial configuration may be addressed by other product specifications or patents.

Is an ethanol-washed buprenorphine implant necessarily infringing?

No. Ethanol washing is required only by claims 8 and 9. An implant can still implicate claim 1 without ethanol washing if it satisfies all limitations of that independent claim.

Can an injectable depot buprenorphine product infringe this patent?

The supplied claims are directed to subcutaneous implantation of an EVA matrix. An injectable depot generally would not satisfy the implant and EVA-matrix limitations, although its use could implicate separate patents.

Does expiration of patent 7,736,665 permit immediate generic launch?

No. The applicant must still satisfy FDA approval requirements and clear other unexpired patents, regulatory exclusivity, controlled-substance obligations, manufacturing validation, and any applicable litigation stay.

References

U.S. Patent No. 7,736,665. (2010). Implantable device for delivery of buprenorphine. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2016). Probuphine prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent expiration guidance. USPTO.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
21 U.S.C. §355. New drugs and abbreviated new drug applications.
35 U.S.C. §271. Infringement of patent.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003240493	⤷ Start Trial
Australia	2008212011	⤷ Start Trial
Canada	2487577	⤷ Start Trial
Cyprus	1120510	⤷ Start Trial
Denmark	2561860	⤷ Start Trial
European Patent Office	1509182	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,736,665

Summary for Patent: 7,736,665